Submitted:
12 November 2026
Posted:
13 November 2026
You are already at the latest version
Abstract
Resmetirom and semaglutide are approved for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis. Guidance increasingly relies on non-invasive tests (NITs) rather than repeat biopsy to monitor response. Serial changes in FIB-4, vibration-controlled transient elastography (VCTE) and magnetic resonance elastography are prognostic for fibrosis progression and liver-related events. However, short-term variability is substantial. VCTE stiffness showed a reproducibility coefficient above 55%, whereas enhanced liver fibrosis (ELF) was markedly more stable. The consensus 30% stiffness-reduction threshold therefore lies within measurement noise. Weight loss and falling aminotransferases may shift NITs independently of fibrosis regression, and FIB-4–stiffness discordance affects about 30% of patients. Serial NITs are valuable prognostic tools but insufficient as stand-alone response measures. Standardised acquisition, variability-aware thresholds and paired complementary tests are advisable pending validation against histology and clinical outcomes.
Keywords:
MASLD
; MASH
; liver fibrosis
; non-invasive tests
; transient elastography
; reproducibility
; resmetirom
; semaglutide
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.